



Report Cover Sheet

Report to:	Trust Board	
Date of the Meeting:	30 September 2020	
Agenda Item:	P1-142-20	
Title:	New Consultant Appointments	
Report prepared by:	Gary Watson , Catherine Hignett-Jones	
Executive Lead:	Jayne Shaw	
Status of the Report:	Public	Private

Paper previously considered by:	
Date & Decision:	

Purpose of the Paper/Key Points for Discussion:	To provide an overview consultant biographies for new appointments since April 2020.
---	--

Action Required:	Discuss	
	Approve	
	For Information/Noting	Yes

Next steps required	
---------------------	--

The paper links to the following strategic priorities (please tick)

Deliver outstanding care locally	X	Collaborative system leadership to deliver better patient care	X
Retain and develop outstanding staff	X	Be enterprising	
Invest in research & innovation to deliver excellent patient care in the future	X	Maintain excellent quality, operational and financial performance	X

The paper relates to the following Board Assurance Framework (BAF) Risks

BAF Risk	Please Tick
1. If we do not optimise quality outcomes we will not be able to provide outstanding care	
2. If we do not prioritise the costs of the delivering the Transforming Cancer Care Programme we will not be able to maintain our long-term financial strength and make appropriate strategic investments.	
3. If we do not have the right infrastructure (estate, communication & engagement, information and technology) we will be unable to deliver care close to home.	
4. If we do not have the right innovative workforce solutions including education and development, we will not have the right skills, in the right place, at the right time to deliver the outstanding care.	X
5. If we do not have an organisational culture that promotes positive staff engagement and excellent health and well-being we will not be able to retain and attract the right workforce.	
6. If we fail to implement and optimise digital technology we will not deliver optimal patient outcomes and operational effectiveness.	
7. If we fail to position the organisation as a credible research partner we will limit patient access to clinical trials and affect our reputation as a specialist centre delivering excellent patient care in the future.	X
8. If we do not retain system-side leadership, for example, SRO for Cancer Alliance and influence the National Cancer Policy, we will not have the right influence on the strategic direction to deliver outstanding cancer services for the population of Cheshire & Merseyside.	
9. If we do not support and invest in entrepreneurial ideas and adapt to changes in national priorities and market conditions we will stifle innovative cancer services for the future.	
10. If we do not continually support, lead and prioritise improved quality, operational and financial performance, we will not provide safe, efficient and effective cancer services.	X

Equality & Diversity Impact Assessment		
Are there concerns that the policy/service could have an adverse impact on:	YES	NO
Age		No
Disability		No
Gender		No
Race		No
Sexual Orientation		No
Gender Reassignment		No
Religion/Belief		No
Pregnancy and Maternity		No

If YES to one or more of the above please add further detail and identify if a full impact assessment is required.

Introduction

This paper provides an update to the Trust Board on consultant appointments in post between 1st April and 30 September 2020. There have been 4 consultant appointments and 1 honorary consultant appointment in this period.

A short biography and account of achievements for each Consultant appointment is provided as follows:

Name	<i>Cree (Saif) , Anthea</i>
Job Title	<i>Consultant Clinical Oncologist</i>
Qualifications	<ul style="list-style-type: none">• <i>PhD , University of Manchester (pending)</i>• <i>McChB, University of Liverpool</i>• <i>Bsc. Hons Genetics, University of Liverpool</i>
Speciality	<i>Gynae and Breast</i>
GMC number	<i>6115032</i>
Membership/Appointments	<i>Royal College of Radiology</i>
Details	<i>Previously employed by The Christie NHS Foundation Trust as Clinical Research Fellow in Radiotherapy Related Research, studying for PhD in Advanced Radiotherapy in cervical cancer.</i>

Name	<i>Boon, Cheng</i>
Job Title	<i>Consultant Clinical Oncologist</i>
Qualifications	<ul style="list-style-type: none">• <i>FRCR, West Midlands</i>• <i>MBChB, University of Manchester</i>• <i>CRE, MHRA London</i>
Speciality	<i>UGI</i>
GMC number	<i>6147331</i>
Membership/Appointments	<i>Royal College of Radiology</i>
Details	<i>Previously undertaken work as Locum via an agency, providing supervision of patients and treatments with advanced, complex chemoradiotherapy for UGI cancers at CCC. Prior to this Dr Boon was employed at Worcestershire Acute NHS Trust as Consultant Clinical Oncologist with a speciality in Head and Neck, Upper GI & Lymphoma</i>

Name	<i>Shallcross, Victoria</i>
Job Title	<i>Consultant Clinical Oncologist</i>
Qualifications	<ul style="list-style-type: none"> • <i>FRCR</i> • <i>MRCP</i> • <i>McChB, University of Liverpool</i> • <i>Bsc. Pharmacology, University of Liverpool</i>
Speciality	<i>Lymphoma and LGI</i>
GMC number	<i>7038241</i>
Membership/Appointments	<i>Royal College of Radiologists</i>
Details	<p><i>Dr Shallcross was previously employed by St Helens and Knowsley NS Foundation Trust as Clinical Oncology Specialist Registrar training at CCC, rotating through oncology sub-specialities from ST3-+ST7 for a series of 3 or 6 monthly rotations. During final year of training, focused on lower GI malignancies and radiotherapy for haemato-oncology.</i></p>

Name	<i>Dr Chloë May</i>
Job Title	<i>Consultant Clinical Oncologist</i>
Qualifications	<ul style="list-style-type: none"> • <i>FRCR</i> • <i>MRCP</i> • <i>MBBS,</i> • <i>Bsc</i>
Speciality	<i>Neuro Oncology Central Nervous System (CNS)</i>
GMC number	<i>7075192</i>
Membership/Appointments	<i>Royal College of Radiologists</i>
Details	<p><i>Dr May was previously employed by St Helens and Knowsley NHS Foundation Trust as specialist registrar within the neuro-oncology team at CCC.</i></p> <p><i>Dr May specialises in treating CNS tumours including primary and secondary brain cancer, spinal cancer and benign brain tumours, utilising radiotherapy and chemotherapy.</i></p>

Honorary Contract Biographies

Name	<i>Christian H. H. Ottensmeier</i>
Job Title	<i>Professor in Immuno-oncology, Consultant in Medical Oncology</i>
Qualifications	<i>MD PhD FRCP</i>
Speciality	<i>Medical Oncology</i>
GMC number	<i>4077392</i>
Tumour Site(s)	<i>Head & Neck cancer, Lung cancer</i>
Details	<p><i>Dr Ottensmeier has been appointed to Professor of Immuno-Oncology at the University of Liverpool and the Head and Neck Institute. Dr Ottensmeier's particular interest is the understanding and improvement of immune responses in patients; with the aim to develop immunotherapies against solid cancers</i></p> <p><i>Dr Ottensmeier was previously employed at University of Southampton where he developed a research focussed melanoma service with a specialist interest in ocular melanoma manages a broad portfolio of clinical trials in solid cancers; he has co-developed a number of national NCRI studies in melanoma and lung cancer.</i></p> <p><i>He has served on a number of national and international peer review committees as well as on advisory boards and DSMBs for industry led studies; he is a member Cancer Immunoguiding panel of the European "CIMT" collaborative, a member of EATI and of the editorial boards for the Journal of Translational Immunology, Cancer Immunology & Immunotherapy, and the newly founded open source BSI Journal "Immunotherapy Advances".</i></p>